載入...
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercia...
Na minha lista:
| 發表在: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5987753/ https://ncbi.nlm.nih.gov/pubmed/29910620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S145039 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|